X
Access Company Profiles

Get business overview, business operations details specific to this market, products and services, latest developments and more...

Business Email

Select Companies

 

Biologics CDMO Companies (2024 - 2029)

Several companies are making significant strides in the biotechnology industry, with some focusing on contract manufacturing, while others are concentrating on pharmaceuticals. These corporations are driving innovation and growth, offering a range of services from drug development to biopharmaceuticals. The industry is highly competitive, with firms continuously striving for advancements in technology and processes to stay ahead. The immense contributions of these businesses are propelling the biotechnology sector forward.

Home Market Analysis Packaging Research Contract Packaging Research Biologics CDMO Market Companies

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Top Companies in Biologics CDMO Market

This report lists the top Biologics CDMO companies based on the 2023 & 2024 market share reports. Mordor Intelligence expert advisors conducted extensive research and identified these brands to be the leaders in the Biologics CDMO industry.

  1. Boehringer Ingelheim Group

  2. Wuxi Biologics (Cayman) Inc.

  3. Samsung Biologics

  4. Lonza Group Ltd

  5. Fujifilm Diosynth Biotechnologies USA Inc.

*Disclaimer: Top companies sorted in no particular order

Biologics CDMO Market Major Players

Biologics CDMO Market Concentration

Biologics CDMO Market Concentration

Biologics CDMO Company List

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Access to New Technologies and Higher Speed of Execution Realized By CDMOs

      2. 4.2.2 Need for High Capital Investments to Develop Capabilities Led to the Demand for the Outsourcing Model

      3. 4.2.3 Lack of In-house Capacity among Emerging Drug Development Companies

    3. 4.3 Market Challenges/ Restraints

      1. 4.3.1 Transfer Complexities and Concerns over the Breach of IP and Patents

      2. 4.3.2 Capacity Issues Related to Large-molecule Drugs

    4. 4.4 Market Opportunities (Emergence of the Concept of Biosimilars Co-development and Designer Cell Lines)

    5. 4.5 Key Considerations Involved in the Selection of Biologics CDMO Vendors

    6. 4.6 Business Model Analysis - Value Added, Flexible Capacity Risk Sharing, and In-time Manufacturing

    7. 4.7 Key Trends in Biopharmaceutical Industry

    8. 4.8 Coverage on the Current Use of Biologics for Different Types of Disease Treatment

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Type

      1. 5.1.1 Mammalian

      2. 5.1.2 Non-mammalian (Microbial)

    2. 5.2 By Product Type

      1. 5.2.1 Biologics

        1. 5.2.1.1 Monoclonal (Diagnostic, Therapeutic, and Protein-based)

        2. 5.2.1.2 Recombinant Proteins

        3. 5.2.1.3 Antisense and Molecular Therapy

        4. 5.2.1.4 Vaccines

        5. 5.2.1.5 Other Biologics

      2. 5.2.2 Biosimilars

    3. 5.3 By Geography***

      1. 5.3.1 North America

      2. 5.3.2 Europe

      3. 5.3.3 Asia

      4. 5.3.4 Australia and New Zealand

      5. 5.3.5 Latin America

      6. 5.3.6 Middle East and Africa

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles*

      1. 6.1.1 Boehringer Ingelheim Group

      2. 6.1.2 Wuxi Biologics (Cayman) Inc.

      3. 6.1.3 Samsung Biologics

      4. 6.1.4 Lonza Group Ltd

      5. 6.1.5 Fujifilm Diosynth Biotechnologies USA Inc.

      6. 6.1.6 Toyobo Co. Ltd

      7. 6.1.7 Parexel International Corp.

      8. 6.1.8 Icon PLC

      9. 6.1.9 Binex Co. Ltd

      10. 6.1.10 Celonic Group (JRS Pharma Group)

      11. 6.1.11 Rentschler Biopharma SE

      12. 6.1.12 AGC Biologics (AGC Inc.)

      13. 6.1.13 Sandoz AG

      14. 6.1.14 Catalent Inc.

      15. 6.1.15 AbbVie Inc.

  7. 7. VENDOR MARKET SHARE

  8. 8. INVESTMENT ANALYSIS

  9. 9. FUTURE OUTLOOK OF THE MARKET


Specific to Biologics CDMO Market
Need More Details On Market Players And Competitors?
Download PDF

Competitive Landscape Report Includes

Company Profiles (includes Global Level Overview, Market Level Overview, Core Business Segments, Financials, Headcount, Key Information, Market Rank, Market Share, Products and Services, and Analysis of Recent Developments). Key Strategic Moves, Market Share Analysis, Company Landscape, and List of Companies.

Biologics CDMO Market Companies Summary

The demand for services from contract manufacturing and contract development manufacturing organizations is expected to increase due to an increased number of companies in the pharmaceutical sector considering outsourcing services. This is due to the need for businesses to invest additional amounts in complying with regulations imposed on manufacturers. Instead of dealing with these complex regulations, businesses prefer to spend on research and development activities, which are more beneficial overall. The highly regulated manufacturing processes, complicated technology transfer, and IP security concerns impede the anticipated growth and adoption of the market in different regions. Contract manufacturing is becoming a major enabler in the supply chain for businesses looking to reduce supply chain length and improve lead-time efficiency. This is often followed by contract packaging for some pharmaceutical drugs, leading pharmaceutical firms to seek vendors who provide both services, along with quality testing. Contract Development & Manufacturing Organizations (CDMOs) are gaining significant market traction through advanced technology and specialized expertise. This is particularly important for niche CDMOs specializing in one compound or dosage form. With the rising prevalence of infectious diseases and increased demand for novel therapies, pharma and biotech firms requiring higher capital investments for advanced technologies are forming collaborations with CDMOs, further driving the market's growth.

Explore More

Biologics CDMO Companies - Table of Contents

  1. 1. COMPETITIVE LANDSCAPE

    1. 1.1 Company Profiles*

      1. 1.1.1 Boehringer Ingelheim Group

      2. 1.1.2 Wuxi Biologics (Cayman) Inc.

      3. 1.1.3 Samsung Biologics

      4. 1.1.4 Lonza Group Ltd

      5. 1.1.5 Fujifilm Diosynth Biotechnologies USA Inc.

      6. 1.1.6 Toyobo Co. Ltd

      7. 1.1.7 Parexel International Corp.

      8. 1.1.8 Icon PLC

      9. 1.1.9 Binex Co. Ltd

      10. 1.1.10 Celonic Group (JRS Pharma Group)

      11. 1.1.11 Rentschler Biopharma SE

      12. 1.1.12 AGC Biologics (AGC Inc.)

      13. 1.1.13 Sandoz AG

      14. 1.1.14 Catalent Inc.

      15. 1.1.15 AbbVie Inc.

Biologics CDMO Companies FAQs

Boehringer Ingelheim Group, Wuxi Biologics (Cayman) Inc., Samsung Biologics, Lonza Group Ltd and Fujifilm Diosynth Biotechnologies USA Inc. are the major companies operating in the Biologics CDMO Market.

Biologics CDMO Market Report Snapshots

Biologics CDMO Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)